Siu, K T
Ramachandran, J
Yee, A J
Eda, H
Santo, L
Panaroni, C
Mertz, J A
Sims III, R J
Cooper, M R
Raje, N
Article History
Received: 30 June 2016
Revised: 12 October 2016
Accepted: 7 November 2016
First Online: 28 November 2016
Competing interests
: JAM, RJS and MRC are employees and shareholders of Constellation Pharmaceuticals. NR is on advisory boards of Amgen, Bristol-Myers Squibb, Celgene Corporation and Takeda. NR has received research funding from AstraZeneca and Eli Lilly. The remaining authors declare no conflict of interest.